KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Long-Term Investments: 2022-2025

Historic Long-Term Investments for Xenon Pharmaceuticals (XENE) over the last 3 years, with Sep 2025 value amounting to $93.0 million.

  • Xenon Pharmaceuticals' Long-Term Investments fell 37.72% to $93.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $93.0 million, marking a year-over-year decrease of 37.72%. This contributed to the annual value of $127.5 million for FY2024, which is 56.46% down from last year.
  • Per Xenon Pharmaceuticals' latest filing, its Long-Term Investments stood at $93.0 million for Q3 2025, which was down 32.27% from $137.3 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' 5-year Long-Term Investments high stood at $292.8 million for Q4 2023, and its period low was $93.0 million during Q3 2025.
  • Its 3-year average for Long-Term Investments is $149.2 million, with a median of $137.3 million in 2025.
  • Its Long-Term Investments has fluctuated over the past 5 years, first spiked by 127.53% in 2023, then plummeted by 56.46% in 2024.
  • Over the past 4 years, Xenon Pharmaceuticals' Long-Term Investments (Quarterly) stood at $128.7 million in 2022, then surged by 127.53% to $292.8 million in 2023, then slumped by 56.46% to $127.5 million in 2024, then slumped by 37.72% to $93.0 million in 2025.
  • Its Long-Term Investments was $93.0 million in Q3 2025, compared to $137.3 million in Q2 2025 and $141.5 million in Q1 2025.